Compare Kroger Co (KR) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs Spyre Therapeutics Inc. Common Stock — how do they compare? Kroger Co trades at $64.08 (market cap $37.26B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Kroger Co is far larger — about 5.1× Spyre Therapeutics Inc. Common Stock's market cap, and Kroger Co pays a 2.47% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kroger Co for 109 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| KR | SYRE | |
|---|---|---|
Market Cap | $37.26B | $7.35B |
Volume | 10,292,234 | 1,624,631 |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $108.92 |
52-Week Low | $55.53 | $22.18 |
Typical Hold Time | 109 Days | 0 Days |
Enterprise Value | $58.68B | $6.35B |
Dividend Yield | 2.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $60.74, down 2.91% on the day, with a bullish technical signal and a consensus analyst price target of $70.62. The stock shows strong cash flow generation ($2.08B net in 2025) and a low P/S ratio of 0.26, but faces margin pressure with a net income margin of 0.73%. Recent news highlights digital growth initiatives and a focus on everyday low prices under new leadership.
The outlook is balanced: upside exists from valuation support and e-commerce expansion, but risks include integration challenges from acquisitions and softer sales guidance. Analysts are moderately bullish, yet near-term performance hinges on execution against cost pressures and competitive dynamics in the grocery sector.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
